Hints and tips:
Related Special Reports
...AstraZeneca makes 40 per cent of its sales in the US, like many European pharmaceutical companies, and it has sought to justify the increases by comparing Soriot’s pay with US pharma bosses....
...Soriot already earns more than bosses of larger European pharmaceutical companies....
...AstraZeneca has a market capitalisation of £171bn....
...Late last year, AstraZeneca agreed to buy its first vaccine company, Icosovax, in a deal worth up to $1.1bn....
...Miels said that the pharmaceutical company has since “rebuilt” its business in China....
...Swiss company Roche acquired obesity drug developer Carmot Therapeutics for $3.1bn last month, while AstraZeneca signed a $2bn licensing agreement with Eccogene, a Chinese maker of an oral obesity drug in...
...The UK-based pharmaceutical group reported revenue of $12.7bn, well ahead of consensus estimates of $11.9bn....
...The UK-based pharmaceutical group reported revenue of $12.7bn for the first quarter of 2024, an increase of 19 per cent, well ahead of consensus estimates of $11.9bn....
...AstraZeneca has acquired oncology biotech Fusion Pharmaceuticals for $2.4bn to build its expertise and challenge Swiss company Novartis in the developing field of a more targeted form of radiotherapy....
...In February, the UK pharmaceuticals company hit a long-term sales target that once seemed out of reach....
...AstraZeneca has also sought to justify the changes by saying it is competing with US rivals. Like many European pharmaceutical companies, it makes a large proportion of sales in the US....
...AstraZeneca has promised to increase its dividend by 7 per cent this year, ahead of a key shareholder vote on pay for its long-standing chief executive Pascal Soriot....
...The chancellor said that AstraZeneca would invest £650mn in the UK to expand its manufacturing, after the government had encouraged the pharmaceutical company to increase its UK investment....
...AstraZeneca has agreed to buy oncology biotech Fusion Pharmaceuticals for $2.4bn, as it builds its capacity in a developing field of cancer care....
...AstraZeneca’s jab developed with Oxford university was widely used across the world, but sales fell more than 99 per cent to just $12mn in 2023....
...Dato-DXd, which has been developed with Japanese pharmaceutical company Daiichi Sankyo, and Enhertu, another AstraZeneca treatment, are considered by analysts to be potentially high-earning drugs....
...The tribunal ruled that the largest company in the FTSE 100 discriminated against James Muir — a leading scientist who had been developing the pharmaceutical company’s drug, Truqap — on the basis of a disability...
...AstraZeneca chief executive Pascal Soriot said last month that the company planned to build independent drug supply chains for the US and China....
...He insisted the market was “completely open” for investment from multinationals such as AstraZeneca, adding that the pharmaceutical industry did not suffer from the same kind of “tensions” with China faced...
...The deal is expected to close in the first quarter of next year, AstraZeneca said....
...The National Institute for Health and Care Excellence announced on Tuesday that it would not approve the medication Enhertu, developed by pharmaceutical companies Daiichi Sankyo and AstraZeneca, to treat...
...AstraZeneca updated the label to warn recipients of the concern on April 7 and April 15....
...The partnership adds to a flurry of agreements between big pharmaceutical companies and young AI businesses to build novel disease treatments and cut the costs of developing them....
...The Anglo-Swedish drugmaker has partnered with Daiichi Sankyo, the Japanese pharmaceutical company, on the development of two key “antibody drug conjugates”, which use antibodies to deliver a chemotherapy...
...AstraZeneca shares are down about 4.5 per cent in the year so far....
International Edition